Bain’s Biotech Bet Pays Off: Cidara Shares Skyrocket 116%

Bain’s third-quarter filing with the SEC reads like a reality show script. They bought 520,310 shares of Cidara, turning their position into a $289.29 million stake. For context, that’s roughly the price of a modest island in the Caribbean-or, you know, a small biotech acquisition. The $167.48 million gain? That’s not a typo. That’s Wall Street’s version of a “slay” reaction. 💅


